Cabometyx (cabozantinib) — United Healthcare
Gastrointestinal Stromal Tumors (GIST)
Preferred products
- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Initial criteria
- Diagnosis of GIST
- Patient has one of the following: gross residual disease (R2 resection) OR unresectable primary disease OR tumor rupture OR recurrent/metastatic disease
- Disease has progressed on all of the following: Gleevec (imatinib); Sutent (sunitinib); Stivarga (regorafenib); standard dose Qinlock (ripretinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Cabometyx therapy
Approval duration
12 months